• Ole Hilberg, Ulf Simonsen, Roland du Bois, and Elisabeth Bendstrup.
• Aarhus University Hospital, Respiratory Diseases and Allergology, Aarhus, Denmark. olehilbe@rm.dk
• Clin Respir J. 2012 Jul 1;6(3):131-43.

AbstractPirfenidone has been shown in three recently published trials to slow down the progression of the devastating interstitial lung disease, idiopathic pulmonary fibrosis (IPF). The precise mechanisms that initiate and perpetuate the histopathological process leading to lung fibrosis in IPF are still uncertain, but increased concentrations of reactive oxidative species and fibrogenetic factors have been observed in the pulmonary tissue of patients. Although the exact mechanisms of its action are unknown, pirfenidone is a small molecule with antifibrotic and some hydroxyl scavenger properties that has recently been approved in Europe and elsewhere for the treatment of IPF. Along with the new ATS/ERS/JRS/ALAT 2011 statement for 'Evidence Based Guidelines for Diagnosis and Management', there is now a more profound basis for offering IPF patients an evidence-based evaluation and treatment. This review summarizes the background to the recommended use of pirfenidone for the treatment of IPF.© 2012 Blackwell Publishing Ltd.

9 keywords...

hide…